PAVmed Inc. (NASDAQ:PAVM) CFO Dennis M. Mcgrath bought 3,000 shares of PAVmed stock in a transaction on Wednesday, August 23rd. The shares were acquired at an average cost of $4.11 per share, with a total value of $12,330.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of PAVmed Inc. (NASDAQ:PAVM) traded up 3.6463% during mid-day trading on Friday, reaching $4.2495. 17,458 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $3.74 and its 200-day moving average price is $4.76. The company’s market capitalization is $56.65 million. PAVmed Inc. has a one year low of $2.54 and a one year high of $14.49.
PAVmed (NASDAQ:PAVM) last issued its quarterly earnings results on Monday, August 14th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. On average, equities analysts expect that PAVmed Inc. will post ($0.72) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Dennis M. Mcgrath Acquires 3,000 Shares of PAVmed Inc. (PAVM) Stock” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://stocknewstimes.com/2017/08/26/dennis-m-mcgrath-acquires-3000-shares-of-pavmed-inc-pavm-stock.html.
An institutional investor recently bought a new position in PAVmed stock. Fusion Family Wealth LLC purchased a new stake in PAVmed Inc. (NASDAQ:PAVM) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 55,745 shares of the company’s stock, valued at approximately $251,000. Fusion Family Wealth LLC owned about 0.42% of PAVmed as of its most recent SEC filing. Hedge funds and other institutional investors own 0.70% of the company’s stock.
Separately, ValuEngine cut shares of PAVmed from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th.
PAVmed Company Profile
PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.
Receive News & Ratings for PAVmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
